Caribou Biosciences (NASDAQ:CRBU) Downgraded to “Sell” Rating by Wall Street Zen

Caribou Biosciences (NASDAQ:CRBU) was downgraded by research analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Saturday.

Separately, HC Wainwright restated a “buy” rating and issued a $3.00 price target (down from $9.00) on shares of Caribou Biosciences in a research report on Monday, April 28th.

Caribou Biosciences Trading Down 1.0%

Shares of Caribou Biosciences stock opened at $1.98 on Friday. The company’s fifty day simple moving average is $1.67 and its 200-day simple moving average is $1.25. The company has a market cap of $184.38 million, a price-to-earnings ratio of -1.11 and a beta of 2.55. Caribou Biosciences has a 1 year low of $0.66 and a 1 year high of $3.00.

Caribou Biosciences (NASDAQ:CRBU) last released its earnings results on Tuesday, August 12th. The company reported ($0.35) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.40) by $0.05. Caribou Biosciences had a negative return on equity of 62.35% and a negative net margin of 1,800.93%. The business had revenue of $2.67 million for the quarter, compared to the consensus estimate of $1.64 million. As a group, research analysts forecast that Caribou Biosciences will post -1.64 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in CRBU. Next Capital Management LLC acquired a new position in shares of Caribou Biosciences during the 2nd quarter worth approximately $25,000. Creative Planning acquired a new position in shares of Caribou Biosciences during the 2nd quarter worth approximately $25,000. Hudson Bay Capital Management LP acquired a new position in shares of Caribou Biosciences in the second quarter valued at $30,000. Savant Capital LLC acquired a new position in shares of Caribou Biosciences in the second quarter valued at $36,000. Finally, Cerity Partners LLC increased its holdings in shares of Caribou Biosciences by 163.6% in the first quarter. Cerity Partners LLC now owns 40,722 shares of the company’s stock valued at $37,000 after purchasing an additional 25,271 shares during the last quarter. Institutional investors and hedge funds own 77.51% of the company’s stock.

About Caribou Biosciences

Caribou Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma.